The State of Systematic Therapies in Clinic for Hepatobiliary Cancers

References

• Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: an Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma. 2021;8:387–401. doi:10.2147/JHC.S300182
   PubMed Web of Science ®Google Scholar
• Akinyemiju T, Abera S, Ahmed M, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: results From the Global Burden of Disease Study. JAMA Oncol. 2017;3(12):1683–1691. doi:10.1001/jamaoncol.2017.3055
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017;153(4):996–1005.e1001. doi:10.1053/j.gastro.2017.06.012
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013;145(3):521–536. doi:10.1053/j.gastro.2013.06.052
   PubMed Web of Science ®Google Scholar
• Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010;52(2):252–257. doi:10.1016/j.jhep.2009.11.015
   PubMed Web of Science ®Google Scholar
• Kim D, Konyn P, Cholankeril G, Bonham CA, Ahmed A. Trends in the Mortality of Biliary Tract Cancers Based on Their Anatomical Site in the United States From 2009 to 2018. Am J Gastroenterol. 2021;116(5):1053–1062. doi:10.14309/ajg.0000000000001151
   PubMed Web of Science ®Google Scholar
• Hsing AW, Bai Y, Andreotti G, et al. Family history of gallstones and the risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Int j Cancer. 2007;121(4):832–838. doi:10.1002/ijc.22756
   PubMed Web of Science ®Google Scholar
• Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173–184. doi:10.1002/hep.24351
   PubMed Web of Science ®Google Scholar
• Chapman MH, Webster GJ, Bannoo S, Johnson GJ, Wittmann J, Pereira SP. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol. 2012;24(9):1051–1058. doi:10.1097/MEG.0b013e3283554bbf
   PubMed Web of Science ®Google Scholar
• Ulrich F, Pratschke J, Pascher A, et al. Long-term outcome of liver resection and transplantation for Caroli disease and syndrome. Ann Surg. 2008;247(2):357–364. doi:10.1097/SLA.0b013e31815cca88
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75(4):960–974. doi:10.1016/j.jhep.2021.07.004
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang H, Zhang L, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20:203–222.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. New Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808–820. doi:10.1016/S1470-2045(20)30156-X
   PubMed Web of Science ®Google Scholar
• Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79(2):506–515. doi:10.1016/j.jhep.2023.03.003
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence. 2022;1:EVIDoa2100070. doi:10.1056/EVIDoa2100070
   PubMedGoogle Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New Engl J Med. 2018;379(1):54–63. doi:10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296. doi:10.1016/S1470-2045(18)30937-9
   PubMed Web of Science ®Google Scholar
• Demir T, Lee SS, Kaseb AO. Systemic therapy of liver cancer. Adv Cancer Res. 2021;149:257–294.
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: a Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020;38(3):193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Yau T, Kang YK, Kim TY, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: the CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020;6(11):e204564. doi:10.1001/jamaoncol.2020.4564
   PubMed Web of Science ®Google Scholar
• Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021;22(7):977–990. doi:10.1016/S1470-2045(21)00252-7
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Xu J, Shen J, Gu S, et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): a Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res. 2021;27(4):1003–1011. doi:10.1158/1078-0432.CCR-20-2571
   PubMed Web of Science ®Google Scholar
• Kelley RK, Sangro B, Harris W, et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: randomized Expansion of a Phase I/II Study. J Clin Oncol. 2021;39(27):2991–3001. doi:10.1200/JCO.20.03555
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–88. doi:10.1016/j.jhep.2013.02.022
   PubMed Web of Science ®Google Scholar
• Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571–580. doi:10.1016/S1470-2045(20)30011-5
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl J Med. 1996;334(11):693–699. doi:10.1056/NEJM199603143341104
   PubMed Web of Science ®Google Scholar
• O’Donnell JS. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67(1):381–400. doi:10.1002/hep.29485
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang G, Wang Y, et al. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience. oncologist. 2016;21(12):1442–1449. doi:10.1634/theoncologist.2016-0094
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am j Transplantation. 2009;9(8):1920–1928. doi:10.1111/j.1600-6143.2009.02695.x
   PubMed Web of Science ®Google Scholar
• Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient? Am j Transplantation. 2020;20(3):879–883. doi:10.1111/ajt.15617
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;368(6489):367. doi:10.1126/science.abb5060
   PubMedGoogle Scholar
• Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat Cancer. 2021;2(9):891–903. doi:10.1038/s43018-021-00234-4
   PubMedGoogle Scholar
• Liu J, O’Donnell JS, Yan J, et al. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. Oncoimmunology. 2019;8(5):e1581530. doi:10.1080/2162402X.2019.1581530
   PubMed Web of Science ®Google Scholar
• Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(8):565–575. doi:10.1016/S2468-1253(17)30156-5
   PubMed Web of Science ®Google Scholar
• Ricke J, Klümpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164–1174. doi:10.1016/j.jhep.2019.08.006
   PubMed Web of Science ®Google Scholar
• Kawamura Y, Kobayashi M, Shindoh J, et al. Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma. Liver Cancer. 2020;9(6):756–770. doi:10.1159/000510299
   PubMed Web of Science ®Google Scholar
• Tampaki M, Ionas E, Hadziyannis E, Deutsch M, Malagari K, Koskinas J. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cancers. 2020;12(1):212. doi:10.3390/cancers12010212
   PubMed Web of Science ®Google Scholar
• Wehrenberg-Klee E, Goyal L, Dugan M, Zhu AX, Ganguli S. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma. Cardiovascular Interventional Radiol. 2018;41(11):1799–1802. doi:10.1007/s00270-018-1993-1
   PubMed Web of Science ®Google Scholar
• Chao J, Zhu Q, Chen D, et al. Case Report: transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection. Front Oncol. 2021;11:667555. doi:10.3389/fonc.2021.667555
   PubMed Web of Science ®Google Scholar
• Xin H, Zhang C, Ding Z, Zhang M, Ding G, Li N. TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: case reports. Clin Res Hepatol Gastroenterol. 2022;46(1):101777. doi:10.1016/j.clinre.2021.101777
   PubMed Web of Science ®Google Scholar
• Kim HJ, Park S, Kim KJ, Seong J. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiotherapy Oncol. 2018;129(1):130–135. doi:10.1016/j.radonc.2017.11.027
   PubMed Web of Science ®Google Scholar
• Zhong L, Wu D, Peng W, et al. Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma. Front Oncol. 2021;11:686621. doi:10.3389/fonc.2021.686621
   PubMed Web of Science ®Google Scholar
• Juloori A, Katipally RR, Lemons JM, et al. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023;115(1):202–213. doi:10.1016/j.ijrobp.2022.09.052
   PubMed Web of Science ®Google Scholar
• Makuuchi M, Kosuge T, Takayama T, et al. Surgery for small liver cancers. Seminars Surgical Oncol. 1993;9(4):298–304. doi:10.1002/ssu.2980090404
   PubMedGoogle Scholar
• Abu Hilal M, Aldrighetti L, Dagher I, et al. The Southampton Consensus Guidelines for Laparoscopic Liver Surgery: from Indication to Implementation. Ann Surg. 2018;268(1):11–18. doi:10.1097/SLA.0000000000002524
   PubMed Web of Science ®Google Scholar
• Bhutiani N, Scoggins CR, McMasters KM, et al. The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium. Surgery. 2018;163(4):726–731. doi:10.1016/j.surg.2017.10.028
   PubMed Web of Science ®Google Scholar
• Xiangfei M, Yinzhe X, Yingwei P, Shichun L, Weidong D. Open versus laparoscopic hepatic resection for hepatocellular carcinoma: a systematic review and meta-analysis. Surg Endosc. 2019;33(8):2396–2418. doi:10.1007/s00464-019-06781-3
   PubMed Web of Science ®Google Scholar
• Stiles ZE, Glazer ES, Deneve JL, Shibata D, Behrman SW, Dickson PV. Long-Term Implications of Unplanned Conversion During Laparoscopic Liver Resection for Hepatocellular Carcinoma. Ann Surg Oncol. 2019;26(1):282–289. doi:10.1245/s10434-018-7073-6
   PubMed Web of Science ®Google Scholar
• Ballantyne GH. The pitfalls of laparoscopic surgery: challenges for robotics and telerobotic surgery. Surgical Laparoscopy Endoscopy & Percutaneous Techniques. 2002;12(1):1–5. doi:10.1097/00129689-200202000-00001
   PubMed Web of Science ®Google Scholar
• Berguer R, Rab GT, Abu-Ghaida H, Alarcon A, Chung J. A comparison of surgeons’ posture during laparoscopic and open surgical procedures. Surg Endosc. 1997;11(2):139–142. doi:10.1007/s004649900316
   PubMed Web of Science ®Google Scholar
• Idrees K, Bartlett DL. Robotic liver surgery. Surgical Clin North Am. 2010;90(4):761–774. doi:10.1016/j.suc.2010.04.020
   PubMed Web of Science ®Google Scholar
• Cipriani F, Fiorentini G, Magistri P, et al. Pure laparoscopic versus robotic liver resections: multicentric propensity score-based analysis with stratification according to difficulty scores. J Hepato-Biliary-Pancreatic Sci. 2022;29(10):1108–1123. doi:10.1002/jhbp.1022
   PubMed Web of Science ®Google Scholar
• Zhu P, Liao W, Zhang WG, et al. A Prospective Study Using Propensity Score Matching to Compare Long-term Survival Outcomes After Robotic-assisted, Laparoscopic, or Open Liver Resection for Patients With BCLC Stage 0-A Hepatocellular Carcinoma. Ann Surg. 2023;277(1):e103–e111. doi:10.1097/SLA.0000000000005380
   PubMed Web of Science ®Google Scholar
• Kang KJ, Ahn KS. Anatomical resection of hepatocellular carcinoma: a critical review of the procedure and its benefits on survival. World J Gastroenterol. 2017;23(7):1139–1146. doi:10.3748/wjg.v23.i7.1139
   PubMed Web of Science ®Google Scholar
• Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecology Obstetrics. 1985;161:346–350.
   PubMedGoogle Scholar
• Shindoh J, Hasegawa K, Inoue Y, et al. Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma. j Int Hepato Pancreato Biliary Assoc. 2013;15(1):31–39. doi:10.1111/j.1477-2574.2012.00552.x
   Google Scholar
• Shindoh J, Makuuchi M, Matsuyama Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol. 2016;64(3):594–600. doi:10.1016/j.jhep.2015.10.015
   PubMed Web of Science ®Google Scholar
• Zhang XP, Xu S, Lin ZY, et al. Significance of anatomical resection and resection margin status in patients with HBV-related hepatocellular carcinoma and microvascular invasion: a multicenter propensity score-matched study. Int j Surgery. 2023;109(4):679–688. doi:10.1097/JS9.0000000000000204
   PubMed Web of Science ®Google Scholar
• Jung DH, Hwang S, Lee YJ, et al. Small Hepatocellular Carcinoma With Low Tumor Marker Expression Benefits More From Anatomical Resection Than Tumors With Aggressive Biology. Ann Surg. 2019;269(3):511–519. doi:10.1097/SLA.0000000000002486
   PubMed Web of Science ®Google Scholar
• Eguchi S, Kanematsu T, Arii S, et al. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery. 2008;143(4):469–475. doi:10.1016/j.surg.2007.12.003
   PubMed Web of Science ®Google Scholar
• Hidaka M, Eguchi S, Okuda K, et al. Impact of Anatomical Resection for Hepatocellular Carcinoma With Microportal Invasion (vp1): a Multi-institutional Study by the Kyushu Study Group of Liver Surgery. Ann Surg. 2020;271(2):339–346. doi:10.1097/SLA.0000000000002981
   PubMed Web of Science ®Google Scholar
• Tanaka K, Shimada H, Matsumoto C, et al. Anatomic versus limited nonanatomic resection for solitary hepatocellular carcinoma. Surgery. 2008;143(5):607–615. doi:10.1016/j.surg.2008.01.006
   PubMed Web of Science ®Google Scholar
• Famularo S, Di Sandro S, Giani A. Long-term oncologic results of anatomic vs. parenchyma-sparing resection for hepatocellular carcinoma. A propensity score-matching analysis. Eur j Surgical Oncol. 2018;44(10):1580–1587. doi:10.1016/j.ejso.2018.05.018
   PubMed Web of Science ®Google Scholar
• Li SQ, Huang T, Shen SL, et al. Anatomical versus non-anatomical liver resection for hepatocellular carcinoma exceeding Milan criteria. Br J Surg. 2017;104:118–127. doi:10.1002/bjs.10311
   PubMed Web of Science ®Google Scholar
• Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg. 2000;231:544–551. doi:10.1097/00000658-200004000-00014
   PubMed Web of Science ®Google Scholar
• Zhong FP, Zhang YJ, Liu Y, Zou SB. Prognostic impact of surgical margin in patients with hepatocellular carcinoma: a meta-analysis. Medicine. 2017;96(37):e8043. doi:10.1097/MD.0000000000008043
   PubMed Web of Science ®Google Scholar
• O’Donnell JS. Corrigendum to “EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2019;70(4):817. doi:10.1016/j.jhep.2019.01.020
   PubMed Web of Science ®Google Scholar
• Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology. 2013;57(4):1426–1435. doi:10.1002/hep.25832
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236. doi:10.1002/hep.20933
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35(3):421–430. doi:10.1016/S0168-8278(01)00130-1
   PubMed Web of Science ®Google Scholar
• Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38(1):37–51. doi:10.1111/j.1872-034X.2007.00216.x
   PubMed Web of Science ®Google Scholar
• Imai K, Beppu T, Chikamoto A, et al. Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatol Res. 2013;43(8):853–864. doi:10.1111/hepr.12035
   PubMed Web of Science ®Google Scholar
• Doi K, Beppu T, Ishiko T, et al. Endoscopic radiofrequency ablation in elderly patients with hepatocellular carcinoma. Anticancer Res. 2015;35(5):3033–3040.
   PubMed Web of Science ®Google Scholar
• Tsukamoto M, Imai K, Yamashita YI, et al. Endoscopic hepatic resection and endoscopic radiofrequency ablation as initial treatments for hepatocellular carcinoma within the Milan criteria. Surgery Today. 2020;50(4):402–412. doi:10.1007/s00595-019-01903-9
   PubMed Web of Science ®Google Scholar
• Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology. 2010;255:426–433.
   PubMed Web of Science ®Google Scholar
• Sutter O, Calvo J, N’Kontchou G, et al. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: a Retrospective Single-Center Case Series. Radiology. 2017;284(3):877–886. doi:10.1148/radiol.2017161413
   PubMed Web of Science ®Google Scholar
• Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–1354. doi:10.1016/S1470-2045(15)00198-9
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156(2):477–491.e471. doi:10.1053/j.gastro.2018.08.065
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. doi:10.1038/s41571-018-0073-4
   PubMed Web of Science ®Google Scholar
• Greten TF, Lai CW, Li G, Staveley-O’Carroll KF. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. Gastroenterology. 2019;156(2):510–524. doi:10.1053/j.gastro.2018.09.051
   PubMed Web of Science ®Google Scholar
• Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31(4):426–432. doi:10.1200/JCO.2012.42.9936
   PubMed Web of Science ®Google Scholar
• Chen K, Chen G, Wang H, et al. Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: a prospective randomized controlled trial. J Hepatol. 2014;61(6):1304–1311. doi:10.1016/j.jhep.2014.07.026
   PubMed Web of Science ®Google Scholar
• Gabrielson A, Wu Y, Wang H, et al. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Cancer Immunol Res. 2016;4(5):419–430. doi:10.1158/2326-6066.CIR-15-0110
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148:1383–1391.e1386. doi:10.1053/j.gastro.2015.02.055
   PubMed Web of Science ®Google Scholar
• Hao MZ, Lin HL, Chen Q, Ye YB, Chen QZ, Chen MS. Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study. Chinese j Cancer. 2010;29:172–177. doi:10.5732/cjc.009.10410
   PubMedGoogle Scholar
• Pan CC, Huang ZL, Li W, et al. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Chinese j Cancer. 2010;29:596–602. doi:10.5732/cjc.009.10580
   PubMedGoogle Scholar
• Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother. 2008;31(1):63–71. doi:10.1097/CJI.0b013e31815a121b
   PubMed Web of Science ®Google Scholar
• Hui D, Qiang L, Jian W, Ti Z, Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Digestive Liver Dis. 2009;41(1):36–41. doi:10.1016/j.dld.2008.04.007
   Web of Science ®Google Scholar
• Yu X, Zhao H, Liu L, et al. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol. 2014;34(2):194–203. doi:10.1007/s10875-013-9976-0
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–1739. doi:10.1016/S0140-6736(02)08649-X
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–1171. doi:10.1053/jhep.2002.33156
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–442. doi:10.1053/jhep.2003.50047
   PubMed Web of Science ®Google Scholar
• Okusaka T, Kasugai H, Shioyama Y, et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2009;51(6):1030–1036. doi:10.1016/j.jhep.2009.09.004
   PubMed Web of Science ®Google Scholar
• Yu SC, Hui JW, Hui EP, et al. Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. Radiology. 2014;270(2):607–620. doi:10.1148/radiol.13130498
   PubMed Web of Science ®Google Scholar
• Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br. J. Cancer. 2014;111(2):255–264. doi:10.1038/bjc.2014.199
   PubMed Web of Science ®Google Scholar
• Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovascular Interventional Radiol. 2007;30(1):6–25. doi:10.1007/s00270-006-0062-3
   PubMed Web of Science ®Google Scholar
• Llovet JM, Villanueva A, Marrero JA, et al. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology. 2021;73 Suppl 1(S1):158–191. doi:10.1002/hep.31327
   PubMedGoogle Scholar
• Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur. J. Cancer. 2011;47(14):2117–2127. doi:10.1016/j.ejca.2011.05.007
   PubMed Web of Science ®Google Scholar
• Kudo M, Han G, Finn RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology. 2014;60(5):1697–1707. doi:10.1002/hep.27290
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64(5):1090–1098. doi:10.1016/j.jhep.2016.01.012
   PubMed Web of Science ®Google Scholar
• Kudo M, Cheng AL, Park JW, et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol. 2018;3(1):37–46. doi:10.1016/S2468-1253(17)30290-X
   PubMed Web of Science ®Google Scholar
• Kudo M, Kubo S, Takayasu K, et al. Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res. 2010;40(7):686–692. doi:10.1111/j.1872-034X.2010.00674.x
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–1501. doi:10.1136/gutjnl-2019-318934
   PubMed Web of Science ®Google Scholar
• Llovet JM, De Baere T, Kulik L. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–313. doi:10.1038/s41575-020-00395-0
   PubMed Web of Science ®Google Scholar
• Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ. Combined locoregional-immunotherapy for liver cancer. J Hepatol. 2019;70(5):999–1007. doi:10.1016/j.jhep.2019.01.027
   PubMed Web of Science ®Google Scholar
• Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545–551. doi:10.1016/j.jhep.2016.10.029
   PubMed Web of Science ®Google Scholar
• Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol. 2015;21(12):3462–3471. doi:10.3748/wjg.v21.i12.3462
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bustamante J, Castells A. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62–67. doi:10.1002/hep.510290145
   PubMed Web of Science ®Google Scholar
• Deng ZJ, Li L, Teng YX, et al. Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: current Status and Controversy. J Clin Translational Hepatol. 2022;10(1):147–158. doi:10.14218/JCTH.2021.00179
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann Oncol. 2019;30(5):871–873. doi:10.1093/annonc/mdy510
   PubMed Web of Science ®Google Scholar
• Kokudo T, Hasegawa K, Matsuyama Y, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65(5):938–943. doi:10.1016/j.jhep.2016.05.044
   PubMed Web of Science ®Google Scholar
• Wang K, Guo WX, Chen MS, et al. Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: a Large-Scale, Multicenter, Propensity Mathching Score Analysis. Medicine. 2016;95(11):e3015. doi:10.1097/MD.0000000000003015
   PubMed Web of Science ®Google Scholar
• Kaneko S, Tsuchiya K, Yasui Y, et al. Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. Hepatol Res. 2020;50(12):1375–1385. doi:10.1111/hepr.13567
   PubMed Web of Science ®Google Scholar
• Luo JJ, Zhang ZH, Liu QX, Zhang W, Wang JH, Yan ZP. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus. Hepatol Internat. 2016;10(1):185–195. doi:10.1007/s12072-015-9663-8
   PubMed Web of Science ®Google Scholar
• Huang C, Zhu XD, Shen YH, et al. Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomarker Res. 2021;9(1):19. doi:10.1186/s40364-021-00274-z
   PubMed Web of Science ®Google Scholar
• Zhang ZH, Hou SN, Yu JZ, et al. Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: a propensity-score analysis. Front Oncol. 2022;12:1086095. doi:10.3389/fonc.2022.1086095
   PubMed Web of Science ®Google Scholar
• Lencioni R, Kudo M, Ye SL, et al. GIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract. 2014;68(5):609–617. doi:10.1111/ijcp.12352
   PubMed Web of Science ®Google Scholar
• McNamara MG, Slagter AE, Nuttall C, et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur. J. Cancer. 2018;105:1–9. doi:10.1016/j.ejca.2018.09.031
   PubMed Web of Science ®Google Scholar
• Huynh J, Cho MT, Kim EJ, Ren M, Ramji Z, Vogel A. Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function. Therapeut Adv Med Oncol. 2022;14:17588359221116608. doi:10.1177/17588359221116608
   Web of Science ®Google Scholar
• Tsuchiya K, Kurosaki M, Sakamoto A, et al. The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers. 2021;13(11):2608. doi:10.3390/cancers13112608
   PubMed Web of Science ®Google Scholar
• Park MK, Lee YB, Moon H, et al. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation. Dig Dis Sci. 2022;67(10):4939–4949. doi:10.1007/s10620-021-07365-9
   PubMed Web of Science ®Google Scholar
• Finkelmeier F, Scheiner B, Leyh C, et al. Cabozantinib in Advanced Hepatocellular Carcinoma: efficacy and Safety Data from an International Multicenter Real-Life Cohort. Liver Cancer. 2021;10(4):360–369. doi:10.1159/000515490
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Chapin WJ, Hwang WT, Karasic TB, McCarthy AM, Kaplan DE. Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. Cancer Med. 2023;12(1):189–199. doi:10.1002/cam4.4906
   PubMed Web of Science ®Google Scholar
• Choi WM, Lee D, Shim JH, et al. Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: a Real-World Cohort Study. Cancers. 2020;12(7):1968. doi:10.3390/cancers12071968
   PubMed Web of Science ®Google Scholar
• D’Alessio A, Fulgenzi CAM, Nishida N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. Hepatology. 2022;76(4):1000–1012. doi:10.1002/hep.32468
   PubMed Web of Science ®Google Scholar
• Harding JJ, Nandakumar S, Armenia J, et al. Prospective Genotyping of Hepatocellular Carcinoma: clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clin Cancer Res. 2019;25(7):2116–2126. doi:10.1158/1078-0432.CCR-18-2293
   PubMed Web of Science ®Google Scholar
• Horwitz E, Stein I, Andreozzi M, et al. Human and Mouse VEGFA -Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment. Cancer Discovery. 2014;4(6):730–743. doi:10.1158/2159-8290.CD-13-0782
   PubMed Web of Science ®Google Scholar
• Feng J, Lu PZ, Zhu GZ, et al. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma. Acta Pharmacol. Sin. 2021;42(1):160–170. doi:10.1038/s41401-020-0439-x
   PubMed Web of Science ®Google Scholar
• Myojin Y, Kodama T, Maesaka K, et al. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. Clin Cancer Res. 2021;27(4):1150–1161. doi:10.1158/1078-0432.CCR-20-3382
   PubMed Web of Science ®Google Scholar
• Finn RS, Kudo M, Cheng AL, et al. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: from the Phase III REFLECT Study. Clin Cancer Res. 2021;27(17):4848–4858. doi:10.1158/1078-0432.CCR-20-4219
   PubMed Web of Science ®Google Scholar
• Sangro B, Melero I, Wadhawan S, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020;73(6):1460–1469. doi:10.1016/j.jhep.2020.07.026
   PubMed Web of Science ®Google Scholar
• Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nature Med. 2022;28(8):1599–1611. doi:10.1038/s41591-022-01868-2
   PubMed Web of Science ®Google Scholar
• Vogel A, Saborowski A. Current and Future Systemic Therapies in Biliary Tract Cancer. Visceral Medicine. 2021;37(1):32–38. doi:10.1159/000513969
   PubMed Web of Science ®Google Scholar
• Neumann UP, Schmeding M. Role of surgery in cholangiocarcinoma: from resection to transplantation. Best Practice Research Clin Gastroenterol. 2015;29(2):295–308. doi:10.1016/j.bpg.2015.02.007
   PubMed Web of Science ®Google Scholar
• Farges O, Fuks D, Boleslawski E, et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg. 2011;254(5):824–829. doi:10.1097/SLA.0b013e318236c21d
   PubMed Web of Science ®Google Scholar
• Brauer DG, Fields RC, Tan BR, et al. Optimal extent of surgical and pathologic lymph node evaluation for resected intrahepatic cholangiocarcinoma. j Int Hepato Pancreato Biliary Assoc. 2018;20(5):470–476. doi:10.1016/j.hpb.2017.11.010
   Google Scholar
• Sahara K, Tsilimigras DI, Merath K, et al. Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: which Patients Benefit the Most from Nodal Evaluation? Ann Surg Oncol. 2019;26(9):2959–2968. doi:10.1245/s10434-019-07483-9
   PubMed Web of Science ®Google Scholar
• Zhang XF, Xue F, Dong DH, et al. Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. Ann Surg. 2021;274(6):e1187–e1195. doi:10.1097/SLA.0000000000003788
   PubMed Web of Science ®Google Scholar
• Jang JY, Kim SW, Park DJ, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2005;241(1):77–84. doi:10.1097/01.sla.0000150166.94732.88
   PubMed Web of Science ®Google Scholar
• Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg. 2008;248(2):273–279. doi:10.1097/SLA.0b013e31817f2bfd
   PubMed Web of Science ®Google Scholar
• Feng JW, Yang XH, Wu BQ, Jiang Y, Qu Z. Progress in diagnosis and surgical treatment of perihilar cholangiocarcinoma. Gastroenterologia y hepatologia. 2019;42(4):271–279. doi:10.1016/j.gastrohep.2018.11.003
   PubMed Web of Science ®Google Scholar
• Sapisochín G, Fernández de Sevilla E, Echeverri J, Charco R. Liver transplantation for cholangiocarcinoma: current status and new insights. World j Hepatol. 2015;7(22):2396–2403. doi:10.4254/wjh.v7.i22.2396
   PubMedGoogle Scholar
• Uijterwijk BA, Lemmers DHL, Bolm L, et al. Long-term Outcomes After Laparoscopic, Robotic, and Open Pancreatoduodenectomy for Distal Cholangiocarcinoma: an International Propensity Score-matched Cohort Study. Ann Surg. 2023;278(3):e570–e579. doi:10.1097/SLA.0000000000005743
   PubMed Web of Science ®Google Scholar
• Murakami Y, Uemura K, Hayashidani Y, et al. Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma. J Surgical Oncol. 2007;95(3):207–212. doi:10.1002/jso.20668
   PubMed Web of Science ®Google Scholar
• Roa JC, García P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nature Reviews Disease Primers. 2022;8(1):69. doi:10.1038/s41572-022-00398-y
   PubMed Web of Science ®Google Scholar
• Zaidi MY, Maithel SK. Updates on Gallbladder Cancer Management. Curr Oncol Rep. 2018;20(2):21. doi:10.1007/s11912-018-0664-3
   PubMed Web of Science ®Google Scholar
• Lundgren L, Muszynska C, Ros A, et al. Management of incidental gallbladder cancer in a national cohort. Br J Surg. 2019;106(9):1216–1227. doi:10.1002/bjs.11205
   PubMed Web of Science ®Google Scholar
• Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192–202. doi:10.1002/bjs.10776
   PubMed Web of Science ®Google Scholar
• Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a Randomized Phase III Study. J Clin Oncol. 2019;37(8):658–667. doi:10.1200/JCO.18.00050
   PubMed Web of Science ®Google Scholar
• Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–673. doi:10.1016/S1470-2045(18)30915-X
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–1289. doi:10.1016/j.jhep.2014.01.021
   PubMed Web of Science ®Google Scholar
• Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. j Int Hepato Pancreato Biliary Assoc. 2015;17(8):691–699. doi:10.1111/hpb.12450
   Google Scholar
• Fulgenzi CAM, D’Alessio A, Airoldi C, et al. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials. Eur. J. Cancer. 2022;174:57–67. doi:10.1016/j.ejca.2022.06.058
   PubMed Web of Science ®Google Scholar
• DeVreede I, Steers JL, Burch PA. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transplantation. 2000;6(3):309–316. doi:10.1053/lv.2000.6143
   PubMed Web of Science ®Google Scholar
• Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. j Int Hepato Pancreato Biliary Assoc. 2008;10(3):186–189. doi:10.1080/13651820801992542
   Google Scholar
• Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg. 2018;105(7):839–847. doi:10.1002/bjs.10641
   PubMed Web of Science ®Google Scholar
• Merath K, Chen Q, Bagante F, et al. A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma. JAMA Surgery. 2019;154(6):e190571. doi:10.1001/jamasurg.2019.0571
   PubMed Web of Science ®Google Scholar
• Utuama O, Permuth JB, Dagne G, et al. Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: a Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Ann Surg Oncol. 2021;28(4):1939–1949. doi:10.1245/s10434-020-09478-3
   PubMed Web of Science ®Google Scholar
• Cloyd JM, Prakash L, Vauthey JN, et al. The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma. Am J Surg. 2019;218(1):145–150. doi:10.1016/j.amjsurg.2018.08.024
   PubMed Web of Science ®Google Scholar
• Glazer ES, Liu P, Abdalla EK, Vauthey JN, Curley SA. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointestinal Surgery. 2012;16:1666–1671. doi:10.1007/s11605-012-1935-1
   PubMed Web of Science ®Google Scholar
• Yadav S, Xie H, Bin-Riaz I, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis. Eur j Surgical Oncol. 2019;45(8):1432–1438. doi:10.1016/j.ejso.2019.03.023
   PubMed Web of Science ®Google Scholar
• Buettner S, Koerkamp BG, Ejaz A, et al. The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients-A multi-institutional analysis. J Surgical Oncol. 2017;115(3):312–318. doi:10.1002/jso.24524
   PubMed Web of Science ®Google Scholar
• Omichi K, Cloyd JM, Yamashita S, et al. Neutrophil-to-lymphocyte ratio predicts prognosis after neoadjuvant chemotherapy and resection of intrahepatic cholangiocarcinoma. Surgery. 2017;162(4):752–765. doi:10.1016/j.surg.2017.05.015
   PubMed Web of Science ®Google Scholar
• Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020;27(10):3729–3737. doi:10.1245/s10434-020-08486-7
   PubMed Web of Science ®Google Scholar
• Welling TH, Feng M, Wan S, et al. Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma. Liver Transplantation. 2014;20(1):81–88. doi:10.1002/lt.23757
   PubMed Web of Science ®Google Scholar
• Jung JH, Lee HJ, Lee HS, et al. Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma. World J Gastroenterol. 2017;23(18):3301–3308. doi:10.3748/wjg.v23.i18.3301
   PubMed Web of Science ®Google Scholar
• Kuriyama N, Usui M, Gyoten K, et al. Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status. BMC Cancer. 2020;20(1):405. doi:10.1186/s12885-020-06895-1
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New Engl J Med. 2010;362(14):1273–1281. doi:10.1056/NEJMoa0908721
   PubMed Web of Science ®Google Scholar
• Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br. J. Cancer. 2010;103(4):469–474. doi:10.1038/sj.bjc.6605779
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1–10. doi:10.1200/JCO.19.02105
   PubMed Web of Science ®Google Scholar
• Kim RD, Chung V, Alese OB, et al. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol. 2020;6(6):888–894. doi:10.1001/jamaoncol.2020.0930
   PubMed Web of Science ®Google Scholar
• Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611–621. doi:10.1016/S2468-1253(19)30086-X
   PubMed Web of Science ®Google Scholar
• Feng K, Liu Y, Zhao Y, et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J ImmunoTherapy Cancer. 2020;8(1):e000367. doi:10.1136/jitc-2019-000367
   PubMed Web of Science ®Google Scholar
• Ebia MI, Sankar K, Osipov A, Hendifar AE, Gong J. TOPAZ-1: a new standard of care for advanced biliary tract cancers? Immunotherapy. 2023;15(7):473–476. doi:10.2217/imt-2022-0269
   PubMed Web of Science ®Google Scholar
• Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853–1865. doi:10.1016/S0140-6736(23)00727-4
   PubMed Web of Science ®Google Scholar
• Li W, Wang Y, Yu Y, et al. Toripalimab in advanced biliary tract cancer. Innovation. 2022;3(4):100255. doi:10.1016/j.xinn.2022.100255
   Google Scholar
• Lin J, Yang X, Long J, et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surgery Nutrition. 2020;9(4):414–424. doi:10.21037/hbsn-20-338
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu X, Wei S, et al. Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: a Single-Arm, Open-Label, Phase II Study. Front Oncol. 2021;11:751391. doi:10.3389/fonc.2021.751391
   PubMed Web of Science ®Google Scholar
• Dennison L, Mohan AA, Yarchoan M. Tumor and Systemic Immunomodulatory Effects of MEK Inhibition. Curr Oncol Rep. 2021;23(2):23. doi:10.1007/s11912-020-01008-4
   PubMed Web of Science ®Google Scholar
• Ebert PJR, Cheung J, Yang Y, et al. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity. 2016;44(3):609–621. doi:10.1016/j.immuni.2016.01.024
   PubMed Web of Science ®Google Scholar
• Liu L, Mayes PA, Eastman S, et al. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015;21(7):1639–1651. doi:10.1158/1078-0432.CCR-14-2339
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Kim TW, Lee CB, et al. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann Oncol. 2019;30(7):1134–1142. doi:10.1093/annonc/mdz113
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Cope L, Ruggieri AN, et al. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J Clin Invest. 2021;131(24). doi:10.1172/JCI152670.
   Web of Science ®Google Scholar
• Wang K, Liu ZH, Yu HM, et al. Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study. Ther Adv Gastroenterol. 2023;16:17562848231160630. doi:10.1177/17562848231160630
   Web of Science ®Google Scholar
• Chen X, Wu X, Wu H, et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J ImmunoTherapy Cancer. 2020;8(2):e001240. doi:10.1136/jitc-2020-001240
   PubMed Web of Science ®Google Scholar